Cancer accounts for almost 20M new diagnoses and 10M deaths. As treatments have been improved during last decade, the need to closely monitor adverse effects of these therapeutics is more and more recognized.
What does Hilly do?
Contacts patients periodically;
Evaluates the presence of warning signs;
Warns health teams if symptoms suggest chemotherapy and/or immunotherapy complications.
Key advantages
Improve patient safety and experience;
Reduce the time spent on repetitive tasks;
Improve patient stratification
Focus on severe illnesses related symptoms;
Faster detection of severe symptoms;
Reduce pressure on emergency departments and inpatient beds;
Optimize the use of resources, reduce costs and increase capacity.
References
Abdel-Wahab N, Alshawa A, Suarez-Almazor ME. Adverse Events in Cancer Immunotherapy. Adv Exp Med Biol. 2017;995:155-174. doi:10.1007/978-3-319-53156-4_8
Ingrand I, Defossez G, Lafay-Chebassier C, et al. Serious adverse effects occurring after chemotherapy: A general cancer registry-based incidence survey. Br J Clin Pharmacol. 2020;86(4):711-722. doi:10.1111/bcp.14159
Lipitz-Snyderman A, Pfister D, Classen D, et al. Preventable and mitigable adverse events in cancer care: Measuring risk and harm across the continuum. Cancer. 2017;123(23):4728-4736. doi:10.1002/cncr.30916